Overview

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Status:
Not yet recruiting

Trial end date:
2024-04-14

Target enrollment:

Participant gender:

Summary

The main trial objective is to ascertain whether the metabolism activity of selected cytochrome (CYP) isozymes caffeine (CYP1A2 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug), metopolol (CYP2D6 probe drug), and midazolam (CYP3A probe drug) are similar or different in F4 liver cirrhosis patients on standard therapy compared to healthy subjects.

Phase:

N/A

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Caffeine
Metoprolol
Midazolam
Omeprazole
Warfarin